AstraZeneca Pharma India · NSE: ASTRAZEN · BSE: 506820
Q4 FY26 results · Jan–Mar 2026
AstraZeneca Pharma India reported revenue from operations of ₹578.61 crore (up 20.4% from Q4 FY25) and net profit of ₹44.88 crore (down 23.0% from Q4 FY25) for Q4 FY26 (Jan–Mar 2026), on a standalone basis.
| Item | Q4 FY26 | Q4 FY25 | YoY | Q3 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 578.61 | 480.48 | +20.4% | 611.57 | −5.4% |
| Other income | 5.95 | 16.15 | −63.2% | 5.13 | +16.0% |
| Total income | 584.56 | 496.63 | +17.7% | 616.70 | −5.2% |
| Profit before tax | 58.14 | 78.47 | −25.9% | 46.54 | +24.9% |
| Net profit for the period | 44.88 | 58.25 | −23.0% | 32.59 | +37.7% |
| EPS, basic (₹) | 17.95 | 23.30 | −23.0% | 13.04 | +37.7% |
| Net margin (%) | 7.8 | 12.1 | 5.3 |
Standalone
- Filed with BSE
- 26 May 2026, 19:52 IST
- Board meeting
- 26 May 2026
- Period
- 01 Jan 2026 to 31 Mar 2026
- Review status
- Audited
- Source
- XBRL filing on BSE